MHRA-100316-PIP01-21

Key Facts

Active Substance
Active Substance:
  • latozinemab
Invented Name
Not yet available
PIP Number MHRA-100316-PIP01-21
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Solution for infusion
Therapeutic area
Therapeutic area:
  • Neurology
Conditions / Indications
Conditions / Indications:
  • Treatment of clinically symptomatic or pre-symptomatic frontotemporal dementia (FTD)
Route(s) of administration
Route(s) of administration:
  • Intravenous use
PIP applicant
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):latozinemab.pdf
Published Date 29/07/2022